Diabetic osteopathy and the IGF system in the Goto-Kakizaki rat.

Tashfeen Ahmad, Anna Ugarph-Morawski, Moira Lewitt, Jian Li, Maria Saaf, Kerstin Brismar

Research output: Contribution to journalArticle

Abstract

Objective
Diabetes mellitus is associated with an increased risk of osteopenia, fracture and Charcot arthropathy. Abnormalities of the IGF system commonly observed in diabetes may underlie this “diabetic osteopathy” as IGF-I and its binding proteins (IGFBPs) have been shown to affect osteoblast and osteoclast activity.
Design
In type-2 diabetic and control rats we analyzed IGF-I and IGFBP-1 and -4 levels in serum, and notably, also the IGF-I levels in cortical bone, ankles and vertebrae by immunoassays. Osteopathy was assessed by radiography and dual energy X-ray absorptiometry.
Results
In the diabetic rats IGF-I was significantly reduced in serum and diaphyseal bone while IGFBP-1 and IGFBP-4 were increased in serum. The periosteal and endosteal diameters were increased in the diaphysis of humerus and tibia (changes similar to those in elderly humans) while bone mineral density was reduced in long bone metaphyses and vertebrae.
Conclusions
Our study demonstrates both systemic and local disturbances of the IGF-system in rats with type-2 diabetes, consistent with the observed enhanced endosteal erosion in long bone diaphyses, and osteopenia in metaphyses and vertebrae. Whether similar IGF-system changes contribute to osteopathy in patients with diabetes and if treatment of diabetes can reverse the osteopathy has yet to be explored.
Original languageEnglish
Pages (from-to)404-411
Number of pages8
JournalGrowth Hormone & IGF Research
Volume18
Issue number5
DOIs
Publication statusPublished - 2008
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor I
Carrier Proteins
Diaphyses
Spine
Metabolic Bone Diseases
Bone and Bones
Serum
Joint Diseases
Humerus
Photon Absorptiometry
Osteoclasts
Osteoblasts
Tibia
Immunoassay
Ankle
Radiography
Bone Density
Type 2 Diabetes Mellitus

Keywords

  • Goto-Kakizaki rat
  • Diabetes mellitus type 2
  • Bone mineral density
  • Insulin-like growth factor
  • Insulin-like growth factor binding protein 1
  • Insulin-like growth factor binding protein 4

Cite this

Ahmad, Tashfeen ; Ugarph-Morawski, Anna ; Lewitt, Moira ; Li, Jian ; Saaf, Maria ; Brismar, Kerstin. / Diabetic osteopathy and the IGF system in the Goto-Kakizaki rat. In: Growth Hormone & IGF Research. 2008 ; Vol. 18, No. 5. pp. 404-411.
@article{0574f3c6bbc946eeb29c160d4367e2e8,
title = "Diabetic osteopathy and the IGF system in the Goto-Kakizaki rat.",
abstract = "ObjectiveDiabetes mellitus is associated with an increased risk of osteopenia, fracture and Charcot arthropathy. Abnormalities of the IGF system commonly observed in diabetes may underlie this “diabetic osteopathy” as IGF-I and its binding proteins (IGFBPs) have been shown to affect osteoblast and osteoclast activity.DesignIn type-2 diabetic and control rats we analyzed IGF-I and IGFBP-1 and -4 levels in serum, and notably, also the IGF-I levels in cortical bone, ankles and vertebrae by immunoassays. Osteopathy was assessed by radiography and dual energy X-ray absorptiometry.ResultsIn the diabetic rats IGF-I was significantly reduced in serum and diaphyseal bone while IGFBP-1 and IGFBP-4 were increased in serum. The periosteal and endosteal diameters were increased in the diaphysis of humerus and tibia (changes similar to those in elderly humans) while bone mineral density was reduced in long bone metaphyses and vertebrae.ConclusionsOur study demonstrates both systemic and local disturbances of the IGF-system in rats with type-2 diabetes, consistent with the observed enhanced endosteal erosion in long bone diaphyses, and osteopenia in metaphyses and vertebrae. Whether similar IGF-system changes contribute to osteopathy in patients with diabetes and if treatment of diabetes can reverse the osteopathy has yet to be explored.",
keywords = "Goto-Kakizaki rat, Diabetes mellitus type 2, Bone mineral density, Insulin-like growth factor, Insulin-like growth factor binding protein 1, Insulin-like growth factor binding protein 4",
author = "Tashfeen Ahmad and Anna Ugarph-Morawski and Moira Lewitt and Jian Li and Maria Saaf and Kerstin Brismar",
year = "2008",
doi = "10.1016/j.ghir.2008.02.003",
language = "English",
volume = "18",
pages = "404--411",
journal = "Growth Hormone & IGF Research",
issn = "1096-6374",
publisher = "Elsevier B.V.",
number = "5",

}

Ahmad, T, Ugarph-Morawski, A, Lewitt, M, Li, J, Saaf, M & Brismar, K 2008, 'Diabetic osteopathy and the IGF system in the Goto-Kakizaki rat.' Growth Hormone & IGF Research, vol. 18, no. 5, pp. 404-411. https://doi.org/10.1016/j.ghir.2008.02.003

Diabetic osteopathy and the IGF system in the Goto-Kakizaki rat. / Ahmad, Tashfeen; Ugarph-Morawski, Anna; Lewitt, Moira; Li, Jian; Saaf, Maria; Brismar, Kerstin.

In: Growth Hormone & IGF Research, Vol. 18, No. 5, 2008, p. 404-411.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Diabetic osteopathy and the IGF system in the Goto-Kakizaki rat.

AU - Ahmad, Tashfeen

AU - Ugarph-Morawski, Anna

AU - Lewitt, Moira

AU - Li, Jian

AU - Saaf, Maria

AU - Brismar, Kerstin

PY - 2008

Y1 - 2008

N2 - ObjectiveDiabetes mellitus is associated with an increased risk of osteopenia, fracture and Charcot arthropathy. Abnormalities of the IGF system commonly observed in diabetes may underlie this “diabetic osteopathy” as IGF-I and its binding proteins (IGFBPs) have been shown to affect osteoblast and osteoclast activity.DesignIn type-2 diabetic and control rats we analyzed IGF-I and IGFBP-1 and -4 levels in serum, and notably, also the IGF-I levels in cortical bone, ankles and vertebrae by immunoassays. Osteopathy was assessed by radiography and dual energy X-ray absorptiometry.ResultsIn the diabetic rats IGF-I was significantly reduced in serum and diaphyseal bone while IGFBP-1 and IGFBP-4 were increased in serum. The periosteal and endosteal diameters were increased in the diaphysis of humerus and tibia (changes similar to those in elderly humans) while bone mineral density was reduced in long bone metaphyses and vertebrae.ConclusionsOur study demonstrates both systemic and local disturbances of the IGF-system in rats with type-2 diabetes, consistent with the observed enhanced endosteal erosion in long bone diaphyses, and osteopenia in metaphyses and vertebrae. Whether similar IGF-system changes contribute to osteopathy in patients with diabetes and if treatment of diabetes can reverse the osteopathy has yet to be explored.

AB - ObjectiveDiabetes mellitus is associated with an increased risk of osteopenia, fracture and Charcot arthropathy. Abnormalities of the IGF system commonly observed in diabetes may underlie this “diabetic osteopathy” as IGF-I and its binding proteins (IGFBPs) have been shown to affect osteoblast and osteoclast activity.DesignIn type-2 diabetic and control rats we analyzed IGF-I and IGFBP-1 and -4 levels in serum, and notably, also the IGF-I levels in cortical bone, ankles and vertebrae by immunoassays. Osteopathy was assessed by radiography and dual energy X-ray absorptiometry.ResultsIn the diabetic rats IGF-I was significantly reduced in serum and diaphyseal bone while IGFBP-1 and IGFBP-4 were increased in serum. The periosteal and endosteal diameters were increased in the diaphysis of humerus and tibia (changes similar to those in elderly humans) while bone mineral density was reduced in long bone metaphyses and vertebrae.ConclusionsOur study demonstrates both systemic and local disturbances of the IGF-system in rats with type-2 diabetes, consistent with the observed enhanced endosteal erosion in long bone diaphyses, and osteopenia in metaphyses and vertebrae. Whether similar IGF-system changes contribute to osteopathy in patients with diabetes and if treatment of diabetes can reverse the osteopathy has yet to be explored.

KW - Goto-Kakizaki rat

KW - Diabetes mellitus type 2

KW - Bone mineral density

KW - Insulin-like growth factor

KW - Insulin-like growth factor binding protein 1

KW - Insulin-like growth factor binding protein 4

U2 - 10.1016/j.ghir.2008.02.003

DO - 10.1016/j.ghir.2008.02.003

M3 - Article

VL - 18

SP - 404

EP - 411

JO - Growth Hormone & IGF Research

JF - Growth Hormone & IGF Research

SN - 1096-6374

IS - 5

ER -